Enrich Biosystems retweeted
Honored to present our Tarlatamab data in active brain mets & treatment beyond isolated CNS progression at #SNOASCO2026!
Key findings in 91 pts:
✅ 33% intracranial ORR in ACTIVE, radiation-naïve brain mets
✅ No clear ↑ in severe CRS/ICANS w/ CNS radiation concurrent with tarlatamab
✅ Treatment beyond isolated CNS progression feasible: +4.3 mo median additional time on therapy with local therapy
First report of continuing a BiTE beyond CNS progression in SCLC. Manuscript in process. Strong signal. Prospective validation needed. 🧠🫁
Grateful to the SNO/@ASCO chairs & organizers, Dr Hattangadi-Gluth @JHGLab and Dr Naidoo @DrJNaidoo
@DukeCancer @UNC_Health_Care @DukeHealth @DukeMets
Enrich Biosystems retweeted
New #JITC article: "Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy" doi.org/10.1136/jitc-2026-01…
Enrich Biosystems retweeted
In this month’s special issue on immune memory, a Review traces historical developments in #Tcell memory and discusses how new technologies have refined strategies for #vaccines and immunotherapies. @sjturn scim.ag/4p1jXqo
Enrich Biosystems retweeted
New data identifies NDRG3 as a previously undescribed regulator of restimulation-induced cell death in T cells, suggesting NDRG3 as a target for autoimmune disorders and chimeric antigen receptor T cell treatment for cancer. Learn more: ow.ly/ftZf50ZhTii.
Enrich Biosystems retweeted
ADCs as "tumor ecosystem-targeting therapies".
The next wave is already here.
Excellent review on where the field is heading: target expression alone is insufficient to predict activity and multidimensional biomarkers are needed
cell.com/cancer-cell/fulltex… @OncoAlert @BarbaraPistill2
Enrich Biosystems retweeted
A pooled CRISPR screen flags genes that boost CAR-T fitness — but a top hit could be improving cytotoxicity, persistence, proliferation, or some mix of the three. Bulk readouts can't tell you which.
Dr. Brandon Simone (Saar Gill Lab, UPenn) combined an epigenetic modifier CRISPR screen with single-well functional tracking on TROVO to pull that apart — distinguishing edits that drive expansion from those that actually improve killing or persistence, then recovering the high-performing clones for follow-up.
Free webinar, June 25 | 11 AM ET
Register: us06web.zoom.us/webinar/regi…
#CART #CRISPRscreen #CellTherapy #Immunotherapy #FunctionalGenomics #CancerImmunotherapy
Enrich Biosystems retweeted
New #JITC article: "KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion" jitc.bmj.com/content/14/5/e0…












